GEX®: An enabling technology platform for expression of biopharmaceuticals that require a specific and/or fully human glycosylation profile.

The GEX® technology allows the optimization of glycosylation to improve activity and/or other properties such as bioavailability, stability, and/or immunogenicity for better clinical performance.

This technology is based on human cell lines that are optimized for both product quality optimization and fast, high reproducible and high yield glycoprotein manufacturing.

An established fermentation process provides homogenous and stable glycosylation patterns, as well as general consistant batch-to-batch product quality.

The GEX® technology is proven for:

Regulatory Approval/Endorsement

GEX® has regulatory approval by FDA, EMA and German regulatory authorities (PEI, BfArM) for manufacturing of biopharmaceuticals.